Page last updated: 2024-12-08
stachyflin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
stachyflin: from fungus Stachybotrys; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 493326 |
| CHEBI ID | 188701 |
| MeSH ID | M0332738 |
Synonyms (5)
| Synonym |
|---|
| stachyflin |
| 3h-naphtho[1',8a':5,6]pyrano[2,3-e]isoindol-3-one, 1,2,6,6a,7,8,9,9a,10,11,12,13-dodecahydro-5,11-dihydroxy-6a,7,10,10-tetramethyl-, (6ar,7s,9as,11s,13as)- |
| dihydroxy(tetramethyl)[?]one |
| (1s,13r,14s,17s,19s)-10,19-dihydroxy-13,14,18,18-tetramethyl-2-oxa-6-azapentacyclo[11.8.0.01,17.03,11.04,8]henicosa-3,8,10-trien-7-one |
| CHEBI:188701 |
Research Excerpts
Overview
Stachyflin is a new class of hemagglutinin fusion inhibitors of influenza A virus. It has H1 and H2 subtype-specific anti-influenza A virus activity.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Stachyflin is a novel compound having H1 and H2 subtype-specific anti-influenza A virus activity. " | ( Identification of a novel HA conformational change inhibitor of human influenza virus. Fujiwara, T; Hattori, N; Iwasaki, H; Kakui, M; Sugimoto, H; Yoshimoto, J, 1999) | 1.75 |
| "Stachyflin is a new class of hemagglutinin fusion inhibitors of influenza A virus." | ( Stachyflin and acetylstachyflin, novel anti-influenza A virus substances, produced by Stachybotrys sp. RF-7260. II. Synthesis and preliminary structure-activity relationships of stachyflin derivatives. Kamigauchi, T; Kouzuki, S; Minagawa, K, 2002) | 2.48 |
Effects
| Excerpt | Reference | Relevance |
|---|---|---|
| "Stachyflin has no inhibition on H3 subtype influenza A or influenza B viruses." | ( Identification of a novel HA conformational change inhibitor of human influenza virus. Fujiwara, T; Hattori, N; Iwasaki, H; Kakui, M; Sugimoto, H; Yoshimoto, J, 1999) | 1.02 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Although the concentration of III in plasma was above the IC50 against the influenza virus strain used for 6h after the oral administration of III in PEG 400 to uninfected ferrets, no in-vivo anti-influenza-virus activity was observed at the same dosage given 4 times daily for 3 days." | ( Development of anti-influenza drugs: II. Improvement of oral and intranasal absorption and the anti-influenza activity of stachyflin derivatives. Fujioka, T; Fujiwara, T; Hashimoto, N; Hattori, N; Ono, J; Sugimoto, H; Sugita, K; Yagi, S; Yoshimoto, J, 2000) | 0.51 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| xanthenes | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (12)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 6 (50.00) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.88
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.88) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||